Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Abstract

IN THEIR EXCELLENT STUDY (THE GALILEO TRIAL), OGURA and associates prospectively evaluated the efficacy and safety of intravitreal aflibercept (IVA; VEGF Trap-Eye: Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA and Bayer Healthcare Pharmaceuticals, Berlin, Germany) injections in patients with macular edema secondary to central retinal vein… (More)
DOI: 10.1016/j.ajo.2014.12.011

Topics

  • Presentations referencing similar topics